Humoral Hypercalcemia of Malignancy – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Humoral Hypercalcemia of Malignancy – Drugs In Development, 2024 report and make more profitable business decisions.
Humoral hypercalcemia of malignancy (HHM) is caused by too much parathyroid hormone-related peptide (PTHrP) from malignant tumors. Primary hyperparathyroidism, PTH production by malignant cells, local osteolytic hypercalcemia, ectopic hyperparathyroidism, and vitamin D-secreting lymphomas can cause HHM. Symptoms include anxiety, depression, cognitive dysfunction, lethargy, weakness, fatigue, hyporeflexia, confusion, stupor, and in the most severe cases, coma. PTH and vitamin D levels, kidney function, and calcium levels in urine help in its diagnosis. HHM can be treated with zoledronic acid, ibadronate, pamidronate, and etidronate.
The Humoral Hypercalcemia of Malignancy drugs in development market research report provide comprehensive information on the therapeutics under development for Humoral Hypercalcemia of Malignancy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Humoral Hypercalcemia of Malignancy and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Humoral Hypercalcemia of Malignancy | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 5 molecules, with 5 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Humoral Hypercalcemia of Malignancy therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Humoral Hypercalcemia of Malignancy pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Humoral Hypercalcemia of Malignancy treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
CSPC Pharmaceutical Group LtdLuye Pharma Group Ltd
NeuClone Pty Ltd
Sandoz Group AG
XOMA Corp
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Humoral Hypercalcemia of Malignancy reports